Pancreatic Adenocarcinoma Resectable, Neoadjuvant Chemotherapy
Conditions
Keywords
Pancreatic Cancer, Pancreatic Adenocarcinoma, Gemcitabine, Nab-paclitaxel, Modified Folfirinox, Sequential treatment
Brief summary
The prognosis of pancreatic cancer is extremely poor. Current guidelines recommend Nab-paclitaxel, Gemcitabine and modified Folfirinox as the first-line chemotherapeutic regimen. Studies have shown that sequential chemotherapeutic regimen can effectively delay the drug resistance and improve the effect of chemotherapy. Here investigators intend to assess the effect of sequential treatment with Nab-paclitaxel plus Gemcitabine and modified Folfirinox as neoadjuvant chemotherapy for resectable pancreatic adenocarcinoma.
Detailed description
Investigators chose resectable pancreatic adenocarcinoma patients. The planned treatment was given to the participants after randomization. Tumor size, event-free survival, overall survival, drugs related side effects and other endpoints events were recorded and analyzed, to assess the sequential treatment with Nab-paclitaxel plus Gemcitabine and modified Folfirinox could or couldn't benefit the prognosis of resectable pancreatic adenocarcinoma.
Interventions
DRUGAG regimen
Combination of Nab-paclitaxel 125 mg/m\^2 and Gemcitabine 1000 mg/m\^2
DRUGmFolfirinox
Folic acid 400mg/m\^2, 5- fluorouracil 2400mg/m\^2 for 46h, irinotecan 135mg/m\^2 and oxaliplatin 68mg/m\^2
Sponsors
Second Affiliated Hospital, School of Medicine, Zhejiang University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Pathologically (histologically or cytologically) confirmed pancreatic ductal adenocarcinoma (PDAC). * No evidence of distant metastasis (such as liver, peritoneum, lung) evaluated by abdominal contrast-enhanced CT, MRI, and chest CT. PET/CT or other imaging examinations would be used if necessary. * Initial assessment for definitive resectable tumors (resectability judgment is based on CT enhanced scan or magnetic resonance imaging, NCCN2018 first edition standard). * ECOG score 0 or 1. * Serum creatinine level is normal, and serum total bilirubin level is less than 1.5 x ULN. * ALT and AST are less than 2 x ULN. * If biliary obstruction is observed, biliary decompression should be performed when the patient is randomly assigned to receive neoadjuvant chemotherapy. * Leukocyte count (\> 3.5 x 10\^6 /mL), neutrophil count (\> 1.5 x 10\^6 /mL), platelet count (\> 80 x 10\^6 /mL), hemoglobin (\> 9 g/dL). * Signed informed consent.
Exclusion criteria
* History of malignance treatment in the past, excluding basal and cutaneous squamous cell carcinoma, cervical carcinoma in situ, papillary thyroid carcinoma * Tumor is a local recurrent lesion. * Imaging confirmed severe portal hypertension / cavernous transformation. * Ascites * Gastric outlet obstruction * Respiratory failure requires supplementation of oxygen. * Immune deficiency syndrome, such as active tuberculosis and HIV infection. * Hematological precancerous diseases, such as myelodysplastic syndromes. * Major cardiovascular diseases (including myocardial infarction, unstable angina, congestive heart failure, severe uncontrolled arrhythmia) during the past six months of enrollment. * Evidence of clinical-related or previous interstitial lung disease, such as noninfectious pneumonia or pulmonary fibrosis, or baseline chest CT scan or chest X-ray findings * Previous or physical findings of central nervous system disease, except for adequately treated (e.g. primary brain tumors, uncontrolled seizures or strokes with standard medications) * Preexisting neuropathy \> 1 (NCI CTCAE). * Allograft requires immunosuppressive therapy or other major immunosuppressive therapies. * Severe serious wounds, ulcers or fractures. * Confirmed coagulant disease. * Clinical evaluation is unacceptable.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| event-free survival (EFS) | From randomization to any of the following events: progression of disease that precludes resection, local or distant recurrence, or death due to any cause, whichever occurs first. Up to approximately 60 months. | Event-Free Survival assessed by the investigator according to RECIST 1.1 by investigator, defined as the time from randomization to any of the following events: progression of disease that precludes resection, local or distant recurrence, or death due to any cause, whichever occurs first. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | From randomization to death due to any cause. Up to approximately 60 months. | Overall survival, the time from randomization to death due to any cause |
| Objective response rate | From randomization to the end of neoadjuvant therapy. Up to approximately 60 months. | The proportion of patients with tumor size reduction of a predefined amount and for a minimum time period |
| Carbohydrate antigen 19-9 | Up to approximately 60 months | Serum Carbohydrate antigen 19-9 level |
| Serious adverse events incidence | Up to approximately 60 months | The proportion of patients with grade 3/4 adverse events |
Countries
China
Outcome results
None listed